Sage Journals: Discover world-class research

Abstract

Precision medicine aims to fix what is wrong with today’s healthcare: a lack of targeted interventions tailored to the person. It encompasses many aspects of health; chief among these is one’s genetic profile. Researchers are making progress as gene-sequencing technologies get better and cheaper. Although there is cause for optimism, as several initiatives at Sunnybrook Research Institute show, scientific, systemic, and logistical challenges must be surmounted before advances can be integrated into the clinic. Despite these barriers, precision medicine is the only way forward.

Get full access to this article

View all access options for this article.

References

President Obama’s Precision Medicine Initiative. Available at: https://www.whitehouse.gov/the-press-office/2015/01/30/fact-sheet-president-obama-s-precision-medicine-initiative.

Available at: https://www.genome.gov/27563453/2016-news-release-new-nih-research-program-targets-the-genomic-basis-for-human-disease/.

Henry

Azzouz

Desta

. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol. 2012;30(9):936–942.

Chirgwin

Giobbie-Hurder

Coates

. Treatment adherence and its impact on disease-free survival in the breast international group 1-98 Trial of tamoxifen and letrozole, alone and in sequence. J Clin Oncol. 2016. pii: JCO638619. [Epub ahead of print].

The Cost of Sequencing a Human Genome. Available at: https://www.genome.gov/27565109/the-cost-of-sequencing-a-human-genome/.

Collins

Ylanko

Geng

Andrews

. A versatile cell death screening assay using dye-stained cells and multivariate image analysis. Assay Drug Dev Technol. 2015;13(9):547–557.

Ernster

Ballard-Barbash

Barlow

. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002;94(20):1546–1554.

Sanders

Schuyler

Dupont

Page

. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. 2005;103:2481–2484.

Narod

Iqbal

Giannakeas

Sopik

Sun

. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol. 2015;1(7):888–896.

10.

Rakovitch

Nofech-Mozes

Narod

. Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis. Breast Cancer Res Treat. 2013;138(2):581–590.

11.

Sadeghi-Naini

Sannachi

Pritchard

. Early prediction of therapy responses and outcomes in breast cancer patients using quantitative ultrasound spectral texture. Oncotarget. 2014;5(11):3497–3511.